Adverse Event Clinical Research, published by HL7 International / Biomedical Research and Regulation. This guide is not an authorized publication; it is the continuous build for version 1.0.1 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/fhir-ae-research-ig/ and changes regularly. See the Directory of published versions
Page standards status: Informative |
Generated Narrative: MedicationAdministration
Resource MedicationAdministration "medication-administration-kadcyla-reduced"
status: completed
Concept |
KADCYLA (RxNorm#1371046) |
subject: Patient/patient-example-kaitlyn-b " BOUNCE"
occurence: 2020-05-20
performer
Actors
Reference Practitioner/practitioner-oncology-nurse-jane " NURSE"
request: MedicationRequest/medication-request-example-kadcyla
note: reduced dose of 3.0mg administered by continuous infusion. Patient tolerated infusion without side effects. (By Practitioner/practitioner-oncology-nurse-jane @2020-05-20)
Route | Dose |
Intravenous route (qualifier value) (SNOMED CT#47625008) | 3 mg (Details: UCUM code mg = 'mg') |